Resolving stagnation

The term 'Resolving stagnation' does not correspond to a known biological molecule, receptor, enzyme, or protein target in contemporary pharmacology or molecular biology (UniProt Consortium, 2024; Armstrong et al., 2024). It is primarily a conceptual therapeutic goal or descriptive phrase used in Traditional Chinese Medicine (TCM) to address clinical states such as 'blood stasis' or 'Qi stagnation,' rather than a discrete molecular entity (World Health Organization, 2019). In a biotechnology and drug discovery context, a valid target must be a specific protein, nucleic acid, or other molecule whose activity can be modulated by a pharmacological agent. Because 'Resolving stagnation' lacks a defined genetic locus, molecular structure, or validated biochemical signaling pathway, it cannot be classified as a therapeutic target. Consequently, there are no specific small molecules, monoclonal antibodies, or other therapeutic agents validated to interact with this phrase as a primary molecular target.

Other names

Blood stasis resolutionQi stagnation resolution

Not applicable as this is not a biological molecule or molecular target.